ANNOVIS BIO INC. COMMON STOCK

Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio

30 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement

24 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio to Participate in the 139th Yale CEO Summit

11 Dec 2023 13:00:00 By Nasdaq GlobeNewswire

Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease

05 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

Annovis Bio Appoints Andrew Walsh as Vice President Finance

01 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections

27 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update

08 Nov 2023 17:00:00 By Nasdaq GlobeNewswire

Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study

12 Oct 2023 08:02:38 By Nasdaq GlobeNewswire

Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update

11 May 2023 07:00:01 By Nasdaq GlobeNewswire

Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans

27 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Annovis Bio, Inc. to present at the Q1 Virtual Investor Summit 

11 Mar 2021 07:05:00 By Nasdaq GlobeNewswire

Annovis Bio to Present at the BIO CEO & Investor Digital Conference

16 Feb 2021 06:45:00 By Nasdaq GlobeNewswire